Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has signed an exclusive collaboration and commercialization agreement with Crucell N.V. for Crucell's rabies monoclonal antibodies (MAbs), next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has signed an exclusive collaboration and commercialization agreement with Crucell N.V. for Crucell's rabies monoclonal antibodies (MAbs), next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.

Crucell has developed a combination of two rabies MAbs that has shown favorable results comparable to current immunoglobulin products in preclinical trials. Phase I clinical trials demonstrated that the MAb-based product is well tolerated, provides the expected immediate passive neutralizing activity, and that it can be safely administered in combination with a rabies vaccine without interfering with the vaccine's ability to induce an active immunity.

Under the terms of the agreement, Crucell will continue to perform the development activities and will manufacture the final product. Crucell will receive a payment of EUR 10 million following the execution of the agreement and would be eligible for milestone payments of up to EUR 66.5 million.